Phase 3 N=450 Evaluation of Skin Testing Reagents for Penicillin Allergy
History of IgE Dependent Reaction to a Penicillin Product
Primary: Negative Predictive Value — 98.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=284 Penicillin Allergy Testing in STD Clinics
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Phase 4 N=23 Penicillin De-labeling in the Pediatric Primary Care Setting
Penicillin Allergy · Penicillin Reaction
Primary: Subjects Who Complete Risk-stratification of Penicillin Allergy in the Pediatric Primary Care Setting — 23 Participants
Phase 4 N=40 Inpatient Penicillin Allergy Delabeling Study
Penicillin Allergy · Penicillin Sensitivity · Penicillin Reaction
Primary: Number of Participants With Confirmed Allergy Status — 28; 6; 6 Participants
N/A N=1,034 The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal
Penicillin Allergy
Primary: Penicillin Allergy Label Removal — 45; 31 Participants
N/A N=205 Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting
Penicillin Allergy
Primary: Penicillin Allergy Label Removal — 201 Participants
N/A N=513 Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients
Penicillin Allergy
Primary: Number of Subjects With Antibiotic Related Adverse Event — 12 participants
Phase 4 N=116 Oral Challenge in the Pediatric ED
Penicillin Allergy · Pediatric Emergency Medicine
Primary: Number of Oral Amoxicillin Challenge Participants Completing Challenge With Insignificant Adverse Result — 114; 2 Participants
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
N/A N=30 Oral Peanut Immunotherapy
Peanut Allergy
Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants
Phase 1 N=15 Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants
N/A N=250 Preoperative Survey to Evaluate Patient Allergy
Allergy Drug · Allergic Reaction · Pediatric
Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies
N/A N=200 Penicillin and Metronidazole in Treatment of Peritonsillar Abscess
Peritonsillar Abscess
Primary: Number of Participants With Recurrence of Peritonsillar Abscess — 10; 10 Participants — p=0.05
Phase 2 N=13 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Peanut Hypersensitivity
Primary: The Percentage of Subjects Who Pass the 20gm Peanut Flour (~50% Peanut Protein) Oral Food Challenge 2-4 Weeks After Discontinuing Peanut OIT Therapy — 3; 1 Participants
Phase 3 N=527 Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Pneumonia
Primary: Treatment Failure at 48 Hours (Two Full Days After Enrollment) — 20; 21 participants
N/A N=30 The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
Phase 2 N=10 Oral Immunotherapy for Peanut Allergy (PMIT)
Food Hypersensitivity
Primary: The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing…
Phase 2 N=10 Preventing Anaphylaxis With Acalabrutinib
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Phase 2 N=14 Omalizumab in the Treatment of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Phase 2 N=54 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Peanut Hypersensitivity · Food Hypersensitivity · Food Allergy
Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg
N/A N=46 Predicting Peanut Anaphylaxis and Reducing Epinephrine
Anaphylaxis Food
Primary: Anaphylaxis Occurrence Rates in Each Group — 9; 10 Participants — p=0.77
Phase 2 N=16 Oral Immunotherapy (OIT) for Peanut Allergy
Peanut Hypersensitivity
Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants
Phase 2 N=253 Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
N/A N=24 Oral Immunotherapy for Peanut and Mammalian Meat Allergies
Food Hypersensitivity
Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams
Phase 2 N=58 Cefixime for Alternative Syphilis Treatment
Syphilis · Early Syphilis
Primary: Treatment Response — 14; 13 Participants
N/A N=59 Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia · Childhood Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Trough Serum Asparaginase Activity ≥ 0.1 IU/mL — 94.5 Percent of participants
Phase 2 N=221 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Peanut Allergy
Primary: Percentage of Treatment Responders at Month 12; Analyzed in Overall Population — 45.3; 41.1; 50.0; 25.0 percentage of participants — p=0.0292
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants